Search Results - "Garant, A"

Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review by Garant, A., Guilbault, C., Ekmekjian, T., Greenwald, Z., Murgoi, P., Vuong, T.

“…•We reviewed clinical interactions between immune checkpoint inhibitors and corticosteroids.•27 articles relating to this question were identified.•These…”
Get full text

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? by Paliga, A, Onerheim, R, Gologan, A, Chong, G, Spatz, A, Niazi, T, Garant, A, Macheto, D, Alcindor, T, Vuong, T

“…Background: There is a growing appreciation for radio-sensitiser use in multi-modal cancer treatment models. Squamous cell anal carcinoma (SCAC) is a rare…”
Get full text

Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer by Gujar, Shashi A, Pan, Da, Marcato, Paola, Garant, Katy A, Lee, Patrick WK

“…Recently reovirus-based oncotherapy has been successfully implemented for the treatment of prostate cancer. In this report, we show that apart from its primary…”
Get full text

Clinical applications of high dose rate endorectal brachytherapy for patients with rectal cancer by Vuong, T., Garant, A., Vendrely, V., Martin, A.-G., Devic, S.

Get full text

Ileostomy Reversal in Rectal Cancer: Outcomes After Neoadjuvant Radiation Therapy by Garant, A, Lamarre, H, Boutros, M, Faria, J, Morin, N, Niazi, T.M, Vasilevsky, C.A, Vuong, T

Get full text

Can Clinical Criteria Estimate Pathological Complete Response in Rectal Cancer Treated With Neoadjuvant High Dose Rate Brachytherapy? by Garant, A, Niazi, T.M, Gologan, A, Spatz, A, Letellier, F, Faria, J, Morin, N, Vasilevsky, C.A, Desgroseilliers, S, Vuong, T

Get full text

EP-1291: Can mucosal criteria estimate response in rectal cancer treated with neoadjuvant chemoradiotherapy? by Garant, A, Niazi, T, Gologan, A, Spatz, A, Faria, J, Morin, N, Vasilevsky, C, Boutros, M, Vuong, T

Get full text

Radiation Therapy as a Curative Modality for Patients With Rectal Cancer by Vuong, T, Nout, R.A, Niazi, T.M, Garant, A, Bujold, A, Martin, A.G, Ferland, S, Stroian, G, Thebaut, J, Sym, A, Devic, S

Get full text

EP-1163 Can concurrent chemoradiation be delayed by induction chemotherapy to treat stage III NSCLC? a pooled analysis by Garant, A, Guilbault, C, Almajed, M, Faria, S, Owen, S, Duclos, M, Ofiara, L, Gruber, J, Hirsh, V, Kopek, N

Get full text

Attenuated reovirus displays oncolysis with reduced host toxicity by Kim, M, Garant, K A, zur Nieden, N I, Alain, T, Loken, S D, Urbanski, S J, Forsyth, P A, Rancourt, D E, Lee, P W K, Johnston, R N

“…Background: Although the naturally occurring reovirus causes only mild symptoms in humans, it shows considerable potential as an oncolytic agent because of its…”
Get full text

PO-0703: Does neoadjuvant chemotherapy improve the pathologic complete remission rate for rectal cancer patients? by Vuong, T, Garant, A, Niazi, T, Kavan, P, Vasilevsky, C.A, Letellier, F, Boutros, M, Batist, G

Get full text

Association of Dosimetric Parameters and Acute Hematologic Toxicity in Anal Canal Patients Treated With Chemoradiation Using 3D-Conformal Versus Intensity Modulated Radiation Therapy Techniques by Gallant, F, Devic, S, Niazi, T, Kafi, K, Garant, A, Lavoie, I, Holcroft, C, Vuong, T

Get full text

Late Anastomotic Dehiscence during Bevacizumab Therapy for Patients with Colorectal Cancer by Garant, A, Des Groseilliers, S, Martin, L, Ferland, É, Vuong, T

Get full text

1242 poster EVALUATION OF RECTUM MOTION DURING PELVIC RADIATION USING CONE-BEAM COMPUTED TOMOGRAPHY (CBCT) by Tomic, N, Garant, A, Thibault, I, Niazi, T, Cuthbert, D, Bahoric, B, Devic, S, DeBlois, F, Vuong, T

Get full text

Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release by Garant, K A, Shmulevitz, M, Pan, L, Daigle, R M, Ahn, D-G, Gujar, S A, Lee, P W K

“…Reovirus is a naturally oncolytic virus that preferentially replicates in Ras-transformed cells and is currently undergoing clinical trials as a cancer…”
Get full text

EP-1384: Concomitant Use of Steroids and Immunotherapy in Cancer Patients: A Comprehensive Review by Garant, A., Vuong, T.

Get full text

Practice Patterns of Primary Stereotactic Radiotherapy for Renal Cell Carcinoma in the United States by Soni, Y.S., Woldu, S., Meng, X., Garant, A., Desai, N.B., Hannan, R., Yang, D.X.

“…Most primary renal cell carcinomas (RCC) are managed locally with surgery, ablative techniques, or active surveillance. However, there is now prospective…”
Get full text

Long-Term Outcomes of SAbR for Metastatic RCC by Zhao, L., Keilty, D., Levesque, M., Stein, M., Christie, A., Garant, A., Brugarolas, J., Timmerman, R.D., Hannan, R.

“…Stereotactic ablative radiation (SAbR) to metastatic lesions from renal cell carcinoma (mRCC) has been shown to delay systemic therapy initiation/rotation, but…”
Get full text

Patient-Reported Outcomes in Rectal Cancer: A Prospective Study of Treatments with Chemoradiotherapy Alone or Followed by Surgery by Martinez, C., Garant, A., Buotros, M., Vasilevsky, C.A.V., Pang, A., Morin, N., Ma, K., Bukera, S., Lecavalier, M., Vuong, T.

“…Rectal cancer local control and outcomes have significantly improved with the combined used of neoadjuvant chemoradiotherapy (CRT) and total mesorectal…”
Get full text

Tradeoffs in Patient Decision Making about Rectal Cancer Treatment: Early Results from The PATHOS Study by Garant, A., Poggi, L., Boutros, M., Ma, K., Vasilevsky, C.A.V., Morin, N., Lecavalier, M., Martin, A.G., Vuong, T.

“…Planned non-operative management (NOM) for patients with rectal cancer is gaining much popularity. However, clinical trial availability, specialized equipment…”
Get full text